During the recent capital markets day (CMD), GCAP announced its updated investment strategy based on three pillars.
Firstly, GCAP maintains its focus on capital-light, scalable opportunities (especially in service-oriented sectors), which should assist its deleveraging efforts (see below). However, it lowered the minimum requirement in terms of targeted exit valuation of businesses to GEL300m (c US$100m, within three to five years) from GEL500m previously (see our review note published in September 2021 for details). GCAP’s management was encouraged to do this following the considerable interest from international investors in its holdings, even for somewhat smaller businesses than originally anticipated.
GCAP plans to enable its large, capital-light portfolio companies to explore regional growth opportunities. In the near term, management sees immediate regional expansion potential in its retail (pharmacy) business, with a five-year target of 400 pharmacies in Georgia (vs 353 currently) and at least 30 stores in Armenia, as well as entry into the Azerbaijan market. GCAP’s CEO believes that this business can expand in a capital-efficient manner, that is it can double its market size by investing US$5–10m in total (including working capital), given the cost of opening a pharmacy in Armenia is c US$50,000. In the longer term, GCAP considers its education business, as well as clinics and diagnostics business promising in terms of regional expansion. It is still in the process of assessing the prospects of the auto services business (where it has invested c US$4.6m in total so far). Beyond the above (and some incremental investments in the renewable energy and education businesses), GCAP is unlikely to make any large new investments in the next three to five years. With respect to more capital-heavy industries (such as hospitals or insurance), GCAP will consider managing third-party capital and/or establishing partnerships. We note that the company is unlikely to purchase an additional stake in BoG (in which it already holds 19.9%) given opposition from the local regulator (as highlighted by GCAP’s CEO during the recent CMD).
Secondly, GCAP has updated its capital management policy to include the NCC ratio as a core element alongside its existing 360-degree framework used to evaluate the optimal price of any potential acquisition. The direction of GCAP’s capital allocations is determined by an assessment of the following: 1) the discount at which GCAP can buy an asset/company in relation to listed peers, 2) the discount to NAV at which GCAP is trading and 3) the discount to fair value at which GCAP’s listed portfolio companies are trading (see our initiation note for a detailed discussion of GCAP’s approach to analysing potential investments).
The NCC ratio allows GCAP to decide how much capital it should invest, ie it acts as a kind of ‘volume button’. The ratio is defined as net debt and guarantees issued at the holding level plus total planned investments, announced buybacks and a US$50m contingency/liquidity buffer divided by portfolio value. GCAP aims to conduct meaningful buybacks and investments at an NCC below 15%, tactical buybacks and investment at an NCC between 15% and 40% and pursue a cash preservation strategy when NCC exceeds 40%. The company is currently focused on deleveraging the holding company by bringing down its NCC ratio below/close to 15% by December 2025 (vs 28% at end March 2022). We understand that the above results from GCAP management’s belief that GCAP’s leverage is one of the factors contributing to its wide discount to NAV (see the discount section for more detail). We agree with this given both the incremental funding risk and the increased NAV volatility arising from meaningful leverage at the holding company level.
Moreover, GCAP plans to reduce and maintain leverage ratios of portfolio companies at their respective target levels. The aggregate net debt to last 12 months (LTM) EBITDA across GCAP’s private large and investment-stage portfolio holdings (including the minority buyout agreement in retail pharmacy) was 2.6x at end-March 2022 (3.7x for all GCAP’s private portfolio companies versus 4.6x and 5.5x at end 2020 and end 2019, respectively, see Exhibit 3). We present the leverage figures of individual holdings together with respective over-the-cycle targets in Exhibit 4. It is worth noting that GCAP’s management does not expect to provide further loans to portfolio companies going forward.
Finally, GCAP will put ESG at the core of its strategy and we discuss its approach to ESG in detail in the investment process section below.
Exhibit 3: Net debt to LTM EBITDA of GCAP’s private portfolio
|
Exhibit 4: Current and targeted leverage of GCAP’s portfolio companies
|
|
|
Source: Georgia Capital data
|
Source: Georgia Capital data. Note: *Adjusted for the capital commitment related to minority stake buyout, excluding which the end-March 2022 ratio would be 0.2x.
|
Exhibit 3: Net debt to LTM EBITDA of GCAP’s private portfolio
|
|
Source: Georgia Capital data
|
Exhibit 4: Current and targeted leverage of GCAP’s portfolio companies
|
|
Source: Georgia Capital data. Note: *Adjusted for the capital commitment related to minority stake buyout, excluding which the end-March 2022 ratio would be 0.2x.
|
Current portfolio positioning
GCAP’s private portfolio at end-March 2022 comprised three large businesses (retail (pharmacy), hospitals and insurance), three investment-stage portfolio companies (clinics and diagnostics, renewable energy and education) and several ‘subscale’ businesses (auto service, beverages, IT outsourcing (previously digital services), housing development and hospitality, see Exhibit 5).
GCAP’s most valuable portfolio holding at present is the largest retail pharmacy chain and wholesale business in Georgia with 353 stores (and six stores in Armenia) with a market share of 35% in 2020, which increased from 30% four years earlier (according to Georgia Healthcare Group’s internal reporting). It also operates seven stores under a franchise agreement with The Body Shop and has one optician outlet under a franchise agreement with Alain Afflelou. The company aspires to be the largest diversified retail operator for human health and wellbeing in the region.
GCAP also owns the largest hospital chain in the country with 2,877 beds representing a 20% market share. The company operates 16 referral hospitals in locations covering 75% of Georgia’s population. Its five-year targets (to 2026) include a 10%+ EBITDA CAGR, EBITDA to operating cash flow ratio of c 85%+ (versus 70.2% in Q122) and a return on invested capital (ROIC) of 13%+ (versus 9.2% in 2021).
The Property and casualty (P&C) insurance business is the top player with more than 65k customers and a 29% market share by gross premiums written in FY21 (according to GCAP). The business has been growing its gross premiums written and net profit by 14% pa and generated an average return on equity of 32% in 2014–21. Its solvency ratio was 174% in Q122 (which it intends to further improve to above 200%) and it had a combined ratio of 81% in FY21 (78% excluding the COVID-19 impact, according to the company). The business plans to enter the regional reinsurance market.
The renewable energy business is a platform for developing hydro and wind power plants across Georgia. It consists of three wholly owned commissioned renewable assets, including the 30MW Mestiachala hydro power plant (HPP), 20MW Hydrolea (acquired in October 2019) and the 21MW Qartli wind farm (acquired in November 2019 through a public auction). The business also has a pipeline of up to 172MW in renewable energy projects at an advanced stage of development.
Moreover, GCAP continues to hold a 19.9% stake in the listed BoG and a 20% stake in the water utility business after the recent sale of its 80% stake.
GCAP’s portfolio at end-March 2022 also included 34 clinics, of which 19 are community clinics and 15 are polyclinics (with two more polyclinics launched in April 2022) serving 595k patients at end-March 2022, which represents a 21% market share. The diagnostics business served 1.2 million patients and performed c 2.6m tests in FY21.
GCAP’s education business is the largest player in the Georgian private K-12 market with a 5% share across five campuses and five brands, with a learner capacity of 5,060, including affordable (3,500), mid-scale (760), premium (400) and international (400) segments. It aims to increase its utilization rate at its current campuses to 94% in 2025/26 from 64% in 2021/22 and drive an EBITDA increase to GEL21m from GEL12m over that period. It has also secured six pipeline projects that represent an additional learner capacity of 3,000 and GEL9.0m in incremental EBITDA by 2025. The business also considers growth through M&A.
Exhibit 5: GCAP’s portfolio at end-March 2022
|
|
Source: Georgia Capital data
|